Express Scripts (ESRX) Issues Quarterly Earnings Results

Express Scripts (NASDAQ:ESRX) issued its quarterly earnings data on Wednesday. The company reported $2.43 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.01, RTT News reports. Express Scripts had a return on equity of 25.49% and a net margin of 4.65%. The company had revenue of $25.56 billion for the quarter, compared to analysts’ expectations of $25.11 billion. During the same period in the previous year, the firm posted $2.51 earnings per share. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis.

Express Scripts stock traded up $1.55 during mid-day trading on Wednesday, reaching $96.97. 4,241,800 shares of the company were exchanged, compared to its average volume of 4,244,859. The company has a quick ratio of 0.59, a current ratio of 0.71 and a debt-to-equity ratio of 0.69. The firm has a market cap of $53.00 billion, a P/E ratio of 13.66, a P/E/G ratio of 1.20 and a beta of 1.01. Express Scripts has a 12-month low of $59.17 and a 12-month high of $97.63.

In other Express Scripts news, insider Christine Houston sold 12,898 shares of the company’s stock in a transaction on Friday, August 10th. The stock was sold at an average price of $85.00, for a total transaction of $1,096,330.00. Following the completion of the sale, the insider now owns 110,908 shares in the company, valued at $9,427,180. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.79% of the stock is owned by corporate insiders.

A number of research analysts have recently commented on ESRX shares. BidaskClub cut Express Scripts from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. Credit Suisse Group cut Express Scripts from an “outperform” rating to a “neutral” rating and upped their target price for the company from $90.00 to $96.50 in a research note on Tuesday, September 18th. Royal Bank of Canada upped their target price on Express Scripts to $94.00 and gave the company an “outperform” rating in a research note on Monday, August 27th. Zacks Investment Research cut Express Scripts from a “hold” rating to a “sell” rating in a research note on Monday, July 23rd. Finally, William Blair raised Express Scripts from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 1st. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $86.36.

Express Scripts Company Profile

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.

Recommended Story: What does cost of debt say about a company’s financial health?

Earnings History for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with's FREE daily email newsletter.

Leave a Reply